|
WO2021028791A1
|
|
An improved process of preparation of ivosidenib
|
|
WO2020225738A1
|
|
Pharmaceutical composition comprising venetoclax
|
|
WO2020212832A1
|
|
Process of preparation of benzimidazole compounds
|
|
WO2020178725A1
|
|
Stable liquid composition of cyclophosphamide
|
|
WO2020003196A1
|
|
Pharmaceutical composition of axitinib
|
|
US2020354361A1
|
|
Solid state forms of venetoclax and its process for the preparation there of
|
|
WO2019138346A1
|
|
Pharmaceutical composition of osimertinib
|
|
WO2019049038A1
|
|
Process for the characterization of glatiramer acetate
|
|
WO2018220513A1
|
|
An improved process for preparation of obeticholic acid
|
|
WO2018069823A1
|
|
Stable pharmaceutical composition comprising telmisartan and amlodipine besylate
|
|
WO2018060916A1
|
|
Process for the preparation of brexpiprazole and intermediates thereof
|
|
WO2018025195A1
|
|
PROCESS FOR THE PREPARATION OF (Sp)-SOFOSBUVIR AND INTERMEDIATES THEREOF
|
|
WO2017221163A1
|
|
Novel salts and polymorphic forms of panobinostat
|
|
WO2017191562A1
|
|
Process for the preparation of olaparib and polymorphs thereof
|
|
US2019002461A1
|
|
Polymorph of Riociguat and its process for the preparation
|
|
EP3156049A1
|
|
Pharmaceutical composition of prasugrel
|
|
US2018235911A1
|
|
Stable pharmaceutical composition of alogliptin and metformin fixed dose combination
|
|
WO2017085568A1
|
|
An improved process and novel polymorphic form of apremilast
|
|
AU2015254949A1
|
|
Novel polymorphic forms of Vortioxetine and its pharmaceutically acceptable salts
|
|
WO2015049645A2
|
|
An improved process for the preparation of dasatinib
|
